Dear Microbiology Insider,
The COVID-19 pandemic has been so all-consuming over the past year that it's easy to forget that there's still a market for diagnostic testing outside of assays for the novel coronavirus.
In fact, the market for biomarker-based infectious disease testing is quite healthy and is expected to produce revenues of almost $15 billion in 2021, according to a new market research report by Kalorama Information, a sister publication to LabPulse.com.
The market is projected to continue growing at a compound annual growth rate of nearly 6% in coming years and generate almost $21 billion in sales by 2027. Find out what's driving the growth in a market analysis by Kalorama publisher Bruce Carlson.
When you're finished reading that story, check back into the Microbiology Community for more intriguing content, including news about the following:
- A U.S. Food and Drug Administration advisory warning of the use of antibody testing to assess immunity levels in people who have received the COVID-19 vaccine
- A recently awarded prize given to pioneers of next-generation sequencing technology
- A low-cost, rapid diagnostic test for COVID-19 that researchers say could deliver results within four minutes
- A new estimate on the market for point-of-care testing that indicates it could hit $29.3 billion in 2020, as new revenues for COVID-19 tests made up for losses in other segments
- A guide on how lab professionals can take the plunge into Twitter, authored by experts from the Cleveland Clinic
Finally, be sure to check out a new article on a survey of lab and science professionals regarding their thoughts on lab automation. The survey found that while many respondents are interested in improving their lab's level of automation, many are concerned about the cost of purchasing new equipment and software.
Get these stories and more in your Microbiology Community!
